Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: lwd who wrote (12)	7/26/1999 2:13:00 AM
From: Vector1	Respond to of 427

lwd GZTC hurt itself with a floorless convert. At HQ the institutional buyers of the convert said they have not shorted the stock. I do not necessarily believe them but I have no evidence to the contrary. The performance of GZTC's clinical lab has also been poor margins are low and they loose money after overhead. It should be sold. In addition the phase III will not report results until midway through 2000. On the other hand the company has had a stream of good news in terms of signing pharma deals and they sucessfully cloned a goat. I think the stock is a good long term buy but I wouldn't blame the shorts on this one.